PT-141 (Bremelanotide): Mechanism & Scientific Evidence
Educational Content Only
The information on this page is based on scientific publications and is for educational purposes only. It does not constitute medical prescription, diagnosis, therapeutic guidance, or recommendation for use. Any clinical intervention must be individualized by a qualified healthcare professional.
⚠️ The information on this page is based on scientific publications and is for educational purposes only. It does not constitute medical prescription, diagnosis, therapeutic guidance, or recommendation for use. Any clinical intervention must be individualized by a qualified healthcare professional.
Scientific guide to PT-141 (Bremelanotide): mechanism of action via melanocortin MC3-R and MC4-R receptors, FDA approval clinical studies for female hypoactive sexual desire and applications described in literature.
Mechanism of Action
PT-141 (Bremelanotide) is a cyclic synthetic analogue of α-MSH (Alpha-Melanocyte Stimulating Hormone), derived from Melanotan II. Unlike conventional treatments for sexual dysfunction, PT-141 does not act via peripheral vasodilation (like PDE5 inhibitors), but centrally, activating melanocortin receptors in the central nervous system — specifically MC3R and MC4R in hypothalamic regions.
Central MC3R/MC4R Activation
PT-141 crosses the blood-brain barrier and activates MC3R/MC4R receptors in the hypothalamus — especially in the paraventricular nucleus (PVN). MC4R in the PVN is strongly associated with sexual function control. Activation of these receptors triggers dopaminergic and noradrenergic cascades that modulate desire, arousal, and genital response.
Dopaminergic Pathway and Central Nitric Oxide
MC4R activation increases dopamine release in mesolimbic circuits (motivation/reward) and stimulates central nitric oxide (NO) production in the hypothalamus. Hypothalamic NO facilitates erection in men and vaginal lubrication/tumescence in women via spinal and autonomic pathways — a distinct and complementary mechanism to PDE5 inhibitors.
- •Only approved central mechanism of action for sexual dysfunction (women) — Vyleesi®
- •Complements PDE5 inhibitors: combines central (desire) + peripheral (vasodilation) action
- •FDA-approved in 2019 as Vyleesi® (bremelanotide SC) for HSDD in premenopausal women
Applications Described in Literature
Hypoactive Sexual Desire Disorder (HSDD) in Women
High evidenceFDA-approved indication. RECONNECT phase III trials with 1,267 premenopausal women demonstrated significant reduction in sexual distress (eDiarySS-D) and increased satisfying sexual encounters. RECONNECT showed: +0.5 satisfying encounters/month and 0.7-point reduction in distress scale vs. placebo.
Erectile Dysfunction in Men (especially PDE5i failure)
Moderate evidencePhase II studies demonstrate PT-141 efficacy in men with erectile dysfunction, including non-responders to PDE5 inhibitors. Central mechanism complements the peripheral pathway of sildenafil/tadalafil. Literature describes SC doses of 1.25–2.5 mg in as-needed use context. Not FDA-approved for this indication.
Relevant Studies
2 curated studies · 2004–2019
Peer-reviewed evidence with PMID verifiable on PubMed
Bremelanotide for Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials
Clayton AH, Kingsberg SA, et al. · Obstetrics & Gynecology
RECONNECT phase III trials: bremelanotide 1.75 mg SC significantly superior to placebo in reducing distress and increasing desire in premenopausal women with HSDD. Basis for 2019 FDA approval.
PT-141: a melanocortin agonist for the treatment of sexual dysfunction
Diamond LE, Earle DC, et al. · Annals of the New York Academy of Sciences
Review of PT-141 mechanism and early clinical data. Demonstrates central MC3R/MC4R activation and efficacy in male erectile dysfunction, including patients unresponsive to sildenafil.
Latest literature review: 2026-04 · PubMed
FAQ
What is PT-141?
PT-141, also known as Bremelanotide, is an agonist of melanocortin receptors (MC3-R and MC4-R). Unlike vasodilatory agents such as PDE5 inhibitors, it acts via the central nervous system. It was approved by the FDA in 2019 (Vyleesi®) for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women.
What is the difference between PT-141 and Sildenafil?
Sildenafil and similar drugs act peripherally via PDE5 inhibition and nitric oxide increase, promoting vasodilation. PT-141 acts centrally via melanocortin receptors in the CNS, modulating sexual desire. These are distinct and complementary mechanisms, as described in clinical literature.
Coming Soon
The premium guide for PT-141 (Bremelanotide) will be available soon.
Already available: Ipamorelin, BPC-157, Semaglutide, GHK-Cu
View Available Peptides →⚠️ Exclusively educational content. Does not constitute medical prescription.